Stay updated on Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The page's revision label updates from Revision: v3.5.3 to Revision: v3.5.4. This indicates a newer version of the page rendering.
    Difference
    0.0%
    Check dated 2026-05-15T06:13:05.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    Updates the ClinicalTrials.gov page’s displayed software/UI revision number from v3.5.2 to v3.5.3. This reflects a platform release rather than a change to the study record itself.
    Difference
    0.0%
    Check dated 2026-04-24T06:33:33.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2 and deleted Revision: v3.5.0 from the history.
    Difference
    0.0%
    Check dated 2026-04-17T02:46:02.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Difference
    0.0%
    Check dated 2026-04-02T15:34:23.000Z thumbnail image
  8. Check
    67 days ago
    Change Detected
    Summary
    Revision: v3.5.0 was added to the Record History, replacing the older v3.4.3 entry.
    Difference
    0.0%
    Check dated 2026-03-19T05:59:36.000Z thumbnail image
  9. Check
    74 days ago
    Change Detected
    Summary
    Footer revision updated from v3.4.2 to v3.4.3. No visible changes to trial information or page behavior.
    Difference
    0.0%
    Check dated 2026-03-12T00:47:11.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.